Table 1.
Completeness of follow-up for dementia and cognitive testing by allocated treatment and occurrence of intracranial events
| Aspirin | Placebo | Total | Total without disabling intracranial eventa | |
|---|---|---|---|---|
| All participants b | 7714 | 7713 | 15 427 | 15 357 |
| Age at randomization, mean (SD), years | 63.2 (9.2) | 63.3 (9.2) | 63.2 (9.2) | 63.2 (9.2) |
| Female sex, n (%) | 2883 (37.4) | 2894 (37.5) | 5777 (37.4) | 5752 (37.5) |
| With linkage to electronic hospital episodes, n (%) | 7691 (99.7) | 7689 (99.7) | 15 380 (99.7) | 15 310 (99.7) |
| In-trial hospitalizations per linked individual, median (IQR)c | 3 (1–6) | 3 (1–6) | 3 (1–6) | 3 (1–6) |
| Any record of hospitalization in trial, n (%) | 6284 (81) | 6265 (81) | 12 549 (81) | 12 479 (81) |
| Disabling intracranial eventa in trial, n (%) | 27 (0.4) | 43 (0.6) | 70 (0.5) | 0 (0.0) |
| Non-disabling intracranial eventd in trial, n (%) | 340 (4.4) | 378 (4.9) | 718 (4.7) | 718 (4.7) |
| Died during follow-up, n (%) | 743 (9.6) | 784 (10.2) | 1527 (9.9) | 1497 (9.7) |
| Surviving to final follow-up (FFU), n (%) | 6971 (90.4) | 6929 (89.8) | 13 900 (90.1) | 13 860 (90.3) |
| Participants surviving to FFU | 6971 | 6929 | 13 900 | 13 860 |
| FFU from participant/carer, n (%) | 5750 (82.5) | 5670 (81.8) | 11 420 (82.2) | 11 404 (82.3) |
| Undertaking Healthy Minds cognitive testing, n (%) | 1347 (19.3) | 1302 (18.8) | 2649 (19.1) | 2647 (19.1) |
| Undertaking TICSm + VF cognitive testing, n (%) | 3186 (45.7) | 3174 (45.8) | 6360 (45.8) | 6355 (45.9) |
| Undertaking any cognitive testing, n (%) | 4533 (65.0) | 4476 (64.6) | 9009 (64.8) | 9002 (64.9) |
| Age at cognitive testing, mean (SD), years | 69.6 (8.1) | 69.4 (8.2) | 69.5 (8.1) | 69.5 (8.1) |
| Education post-16, n (%)e | 2826 (62.3) | 2812 (62.8) | 5638 (62.6) | 5643 (62.6) |
| Disabling intracranial eventa in trial, n (%) | 17 (0.2) | 23 (0.3) | 40 (0.3) | 0 (0.0) |
a
Disabling stroke or subdural haemorrhage.
b
Of the 15 480 participants randomized in ASCEND, 26 participants from the aspirin arm and 27 from the placebo arm had the broad dementia outcome in the eHE data prior to randomization and have been excluded from all the present analyses.
c
Association between at least one post-randomization admission to hospital and randomized allocation to aspirin, rate ratio = 0.99 (95% CI, 0.96–1.03).
d
Non-disabling stroke, transient ischaemic attack, or subdural haemorrhage.
e
Only available in those with cognitive testing, percentage is of the number of individuals undertaking cognitive testing.